1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone has been researched along with propranolol in 1 studies
| Studies (1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone) | Trials (1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone) | Recent Studies (post-2010) (1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone) | Studies (propranolol) | Trials (propranolol) | Recent Studies (post-2010) (propranolol) |
|---|---|---|---|---|---|
| 9 | 0 | 3 | 33,310 | 3,406 | 3,218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Baghdadi, OB; Geldenhuys, WJ; Prater, NI; Van der Schyf, CJ | 1 |
1 other study(ies) available for 1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone and propranolol
| Article | Year |
|---|---|
Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease.
Topics: Alkaloids; Animals; Benzodioxoles; Binding Sites; Blood-Brain Barrier; Cattle; Humans; Hydrogen Bonding; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Piper nigrum; Piperidines; Polyunsaturated Alkamides; Protein Binding; Protein Structure, Tertiary; Serum Albumin, Bovine | 2012 |